P. Shepherd

发表

Granulocytic sarcomas of small intestine and brain are associated with acute myelomonocytic leukaemia with abnormal eosinophils and inversion of chromosome 16.

M. S. Hamilton, P. Shepherd, J. Porter, 1992, Leukemia & lymphoma.

The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha.

J. Hasford, H. Kluin-Nelemans, F. Mahon, 2005, Haematologica.

Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission

J. Goldman, A. Reiter, N. Cross, 2000 .

Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa

J. Klein, D. Marin, J. Goldman, 2003, The Lancet.

Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia

R. Kusec, A. Gaiger, J. Boultwood, 1999, American journal of hematology.

Neutropenia preceding acute lymphoblastic leukaemia.

P. Shepherd, N. Allan, G. Corbett, 1988, Journal of clinical pathology.

Severe cytopenias associated with the sequential use of busulphan and interferon‐alpha in chronic myeloid leukaemia

S. Richards, P. Shepherd, N. Allan, 1994, British journal of haematology.

Successful Use of National Cancer Registry Data to Monitor the Effective Use of Imatinib for Treating Chronic Myeloid Leukaemia

P. Shepherd, M. Drummond, T. Holyoake, 2008, Scottish medical journal.

Clinical Features of CML

P. Shepherd, Mira Farquharson, 2007 .

polyclonal hematopoiesis in the majority patients in cytogenetic remission to imatinib but restoration of cells in some CML - Emergence of clonal cytogenetic abnormalities in Ph

K. Krohn, M. Deininger, H. Al-Ali, 2012 .

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

D. Marin, T. Holyoake, J. Goldman, 2010, Haematologica.

Treatment of CML using IFN-alpha: impact on quality of life.

S. Richards, J. Halsey, J. Homewood, 2003, The hematology journal : the official journal of the European Haematology Association.

Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.

K. Krohn, M. Deininger, D. Niederwieser, 2003, Blood.

Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.

H. Heimpel, R. Peto, J. Hasford, 1997, Journal of the National Cancer Institute.

Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta‐analysis of three randomized trials

H. Heimpel, J. Hasford, J. Godwin, 2000, British journal of haematology.

myeloid leukemia stem cell transplantation and donor lymphocyte infusion in chronic Complete molecular responses are achieved after reduced intensity

C. Crawley, M. Copland, T. Holyoake, 2013 .

Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia.

C. Crawley, M. Copland, T. Holyoake, 2008, Blood.

A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response

R. Clark, T. Holyoake, R. Clark, 2009, Leukemia.

Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups.

S. le Cessie, A. Green, J. Falkenburg, 2004, Blood.

Spontaneous clinical regression in chronic lymphocytic leukaemia

D. Catovsky, P. Shepherd, I. Ribeiro, 2002, British journal of haematology.

Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study

T. Holyoake, M. Drummond, P. Gallipoli, 2011, British journal of haematology.

Idiopathic portal hypertension associated with cytotoxic drugs.

D. Harrison, P. Shepherd, 1990, Journal of clinical pathology.

Early delayed radiation injury to the brainstem after radiotherapy for lymphoma of the tongue and neck.

D. Kean, P. Shepherd, G. Ritchie, 1989, Clinical oncology (Royal College of Radiologists (Great Britain)).

Variable numbers of BCR‐ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon‐α

J. Goldman, A. Reiter, N. Cross, 1995, British journal of haematology.

Treatment of chronic myeloid leukaemia.

P. Shepherd, N. Allan, 1987, Bailliere's clinical haematology.

Analysis of molecular breakpoint and m‐RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival

J. Halsey, P Shepherd, R Suffolk, 1995, British journal of haematology.

a powerful and independent prognostic indicator in chronic myeloid leukemia

L. Campbell, A. Green, J. Szer, 2001 .

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.

M. Baccarani, H. Kluin-Nelemans, G. Rosti, 2001, Blood.

Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase.

P. Mcgale, S. Richards, J. Boultwood, 2000, Blood.

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia.

S. Richards, N C Allan, S M Richards, 1995, Lancet.

Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed

J. Byrne, R. Clark, D. Marin, 2011, Haematologica.

responders : a study of complete cytogenetic α Chronic myeloid leukemia and interferon-

J. Hasford, M. Baccarani, G. Rosti, 2013 .

Systemic mastocytosis presenting as osteoporosis—a case report

P. Shepherd, R. Mathew, V. Dhillon, 2009, Clinical Rheumatology.

Molecular monitoring of complete cytogenetic responders following treatment with imatinib (STI571, Gleevec) for CML: A report from the UKSTI571 study group.

C. Craddock, J. Byrne, R. Clark, 2002 .

chronic myeloid leukemia translocation and provide a powerful and independent prognostic indicator in Deletions of the derivative chromosome 9 occur at the time of the Philadelphia

L. Campbell, A. Green, A. Bench, 2008 .

UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response

S. Richards, N. C. Allan, P. C. A. Shepherd, 1995, The Lancet.

The long term outcome of the patients with chronic myeloid leukemia (CML) who have achieved complete cytogenetic response (CCgR) to interferon-alpha (IFN alpha). A collaborative European study of 317 cases.

M. Baccarani, G. Martinelli, S. Richards, 2001 .

A randomised comparison of low or high dose IFN-alpha in newly diagnosed CML patients shows no difference in major cytogenetic response rate or survival between the two groups - Results of MRC CML V & HOVON 20 trials.

S. Cessie, H. Kluin-Nelemans, S. Richards, 2001 .

Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.

K. Krohn, M. Deininger, D. Niederwieser, 2003, Blood.